NL7601132A - Cytotoxic medicaments bonded to polymeric carrier - e.g. dextran, which is itself bonded to immunoglobulin specific for cells to be killed - Google Patents

Cytotoxic medicaments bonded to polymeric carrier - e.g. dextran, which is itself bonded to immunoglobulin specific for cells to be killed

Info

Publication number
NL7601132A
NL7601132A NL7601132A NL7601132A NL7601132A NL 7601132 A NL7601132 A NL 7601132A NL 7601132 A NL7601132 A NL 7601132A NL 7601132 A NL7601132 A NL 7601132A NL 7601132 A NL7601132 A NL 7601132A
Authority
NL
Netherlands
Prior art keywords
bonded
cells
polymeric carrier
killed
dextran
Prior art date
Application number
NL7601132A
Other languages
Dutch (nl)
Original Assignee
Searle & Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB4695/75A external-priority patent/GB1496011A/en
Application filed by Searle & Co filed Critical Searle & Co
Publication of NL7601132A publication Critical patent/NL7601132A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/44—Antibodies bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6883—Polymer-drug antibody conjugates, e.g. mitomycin-dextran-Ab; DNA-polylysine-antibody complex or conjugate used for therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Peptides Or Proteins (AREA)
  • Polymers With Sulfur, Phosphorus Or Metals In The Main Chain (AREA)
  • Measuring Pulse, Heart Rate, Blood Pressure Or Blood Flow (AREA)
  • Medicinal Preparation (AREA)

Abstract

Cytotoxic agents (I) comprise an immunoglobulin (Ig), specific for the antigens on the surface of the cells which it is intended to kill, to which are covalently bonded 1-10 molecules of a polymeric carrier (VP) having covalently bonded to them in turn 5-500 molecules of a cytotoxic medicament (CD). (VP) has mol. wt. 5000-500000 and contains COOH, NH2 or cycloimidocarbonate gps. for forming the covalent bonds, and (CD) also has NH2 or COOH gps. for forming these bonds. Used for treating neoplastic diseases. The CD/VP bonds are enzymatically cleared when (I) is attached to the target cell, so by use of particular Ig, large amts. of (CD) can be delivered to specific points. The toxicity of (CD) is much lower when bonded in (I) than when used as the free cpd.
NL7601132A 1975-02-04 1976-02-04 Cytotoxic medicaments bonded to polymeric carrier - e.g. dextran, which is itself bonded to immunoglobulin specific for cells to be killed NL7601132A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB4695/75A GB1496011A (en) 1974-11-22 1975-02-04 Defoaming composition

Publications (1)

Publication Number Publication Date
NL7601132A true NL7601132A (en) 1976-08-06

Family

ID=9782062

Family Applications (1)

Application Number Title Priority Date Filing Date
NL7601132A NL7601132A (en) 1975-02-04 1976-02-04 Cytotoxic medicaments bonded to polymeric carrier - e.g. dextran, which is itself bonded to immunoglobulin specific for cells to be killed

Country Status (5)

Country Link
JP (1) JPS51126281A (en)
BE (1) BE838273A (en)
DK (1) DK43676A (en)
NL (1) NL7601132A (en)
SE (1) SE7601125L (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57143326A (en) * 1981-03-03 1982-09-04 Teijin Ltd Polymer linked to cellular toxic substance and its preparation
DE3205847A1 (en) * 1981-05-08 1982-12-16 Farmitalia Carlo Erba S.p.A., 20159 Milano Daunorubicin-protein conjugates
JPS60172935A (en) * 1984-02-16 1985-09-06 Green Cross Corp:The Preparation of composite material of substance having carcinostatic action
JPS611622A (en) * 1984-06-14 1986-01-07 Teijin Ltd Cytotoxic complex and preparation thereof
FR2586564B1 (en) * 1985-09-04 1989-04-07 Pierre Tran Ba Loc IMMUNOSUPPRESSIVE COMPOUNDS AND PROCESS FOR THEIR PREPARATION
JPS62228025A (en) * 1985-12-27 1987-10-06 Teijin Ltd Production of antibody complex
JPH0662438B1 (en) * 1986-08-28 1994-08-17 Teijin Ltd
EP0279862B1 (en) * 1986-08-28 1993-11-03 Teijin Limited Cytocidal antibody complex and process for its preparation
US5149782A (en) * 1988-08-19 1992-09-22 Tanox Biosystems, Inc. Molecular conjugates containing cell membrane-blending agents
JP2626654B2 (en) * 1990-03-31 1997-07-02 科学技術振興事業団 Targeting high molecular weight pharmaceutical compounds and intermediates thereof

Also Published As

Publication number Publication date
SE7601125L (en) 1976-08-05
BE838273A (en) 1976-08-04
JPS51126281A (en) 1976-11-04
DK43676A (en) 1976-08-05

Similar Documents

Publication Publication Date Title
NL7601132A (en) Cytotoxic medicaments bonded to polymeric carrier - e.g. dextran, which is itself bonded to immunoglobulin specific for cells to be killed
SE410312B (en) PROCEDURE FOR MANUFACTURE OF CERTAIN STATED OXIMETERS
ATE199741T1 (en) GENE THERAPEUTICAL TREATMENT OF TUMORS WITH AN ENDOTHELIAL CELL-SPECIFIC, CELL CYCLE-DEPENDENT ACTIVE SUBSTANCE
ATE326242T1 (en) IMPROVEMENTS TO OR RELATED TO DIAGNOSTIC/THERAPEUTIC AGENTS
DE69126124D1 (en) POLYMERS CARRIER FOR RELEASING COVALENT-RELATED ACTIVE SUBSTANCES
SE8900586L (en) COMPOSITION AND PROCEDURES TO PREVENT ADHESION BETWEEN BODY TISSUE
DE69020422T2 (en) Composition in the form of a foam containing 5-aminosalicylic acid for intra-rectal administration.
ATE208632T1 (en) PHOSPHOLIPIDE ADMINISTRATION SYSTEM
ES478710A1 (en) Ornithine and arginine salts of branched chain keto acids and uses in treatment of hepatic and renal disorders
FR2454434A1 (en) MIXED SALTS OF ESSENTIAL OR SEMI-ESSENTIAL AMINO ACIDS AND THE LIKE, NITROGEN FREE, OF SUCH ACIDS, AND THEIR USE IN THE TREATMENT OF RENAL AND HEPATIC DISORDERS
DE69320646D1 (en) METHOD FOR TREATING CANCER BY COMBINATION THERAPY WITH 2'-HALOMETHYLIDEN DERIVATIVES AND AN S- OR M-PHASE-SPECIFIC ANTINEOPLASTIC ACTIVE SUBSTANCE
TR199901949T2 (en) From lymphosis to t�m�rler i�in �areler.
NL7803153A (en) OPTICALLY ACTIVE AMINO ACID-ALMONDIC ACID COMPLEXES, PROCEDURE FOR PREPARING SUCH COMPLEXES, AND PROCEDURE FOR PREPARING OPTICALLY ACTIVE AMINO ACIDS OR ALMOND ACID.
NL155264B (en) PROCESS FOR THE PREPARATION OF A WATER-INSOLUBLE CHELATE OF A BIOLOGICALLY ACTIVE AMINO ACID, ACID AMIDE OR AMINOGLYCOSIDE, AS WELL AS A WHOLE OR PARTLY CONSTITUTED OF SUCH INSOLUBLE CHELATE FORMED.
EP0476953A3 (en) Viral targeted destruction of neoplastic cells
ATE11224T1 (en) WOUND HEALING COMPOSITIONS.
ES483358A1 (en) Use of glutaric acid as a virucidal agent and a composition containing it.
DE59010838D1 (en) Glycosyl-etoposide prodrugs, processes for their preparation and their use in combination with functionalized tumor-specific enzyme conjugates
ES8801984A1 (en) Constant rate release systems
WO1990003172A3 (en) Bile acids for treatment of viral infections
ATE59143T1 (en) COMPOSITION FOR TRANSDERMAL DRUG DELIVERY.
NL166188C (en) METHOD FOR PREPARING A SUBSTANCE-DRUGING MEDICINE, CONTAINING A PURINE-3 ', 5' -CYCLOPHOSPHATE COMPOUND, OBTAINED PREPARED MEDICINE, USING THIS PROCESS AND PROCESS-3-PROCESS -CYCLOPHOSPHATE COMPOUND, SUITABLE FOR USE IN THE SAID METHOD FOR PREPARING A MEDICINAL PRODUCT.
AT328414B (en) PROCESS FOR THE PRODUCTION OF 4,6-DICHLORO-PYRAZOLO- (3,4-D) -PYRIMIDINE OR IT'S NEW 1-ARYL OR 1-ARALKYL DERIVATIVES
AT352883B (en) PROCESS FOR THE PRODUCTION OF A PHARMACEUTICAL ACTIVE AMORPHIC STERYL-BETA-D-GLUCOSIDE-ESTER OR. OF THESE PREPARATIONS INCLUDED
FR2355506A1 (en) IMMUNOTHERAPY ADJUVANT CONTAINING GLYCOLIPID AS ACTIVE INGREDIENT AND PROCESS FOR PREPARATION

Legal Events

Date Code Title Description
BV The patent application has lapsed